Skip to main content
Explore URMC

menu

A Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Subjects with Active Crohn’s Disease

Research Question:
How does treatment with Ustekinumab compare to treatment with Adalimumab in patients with active Crohn's Disease?

Basic Study Information

Purpose:
The purpose of this study is to compare the effectiveness of the drug Ustekinumab to the drug Adalimumab in patients who have moderate to severe Crohn's disease. The study will test Ustekinumab compared to Adalimumab for 56 weeks. To determine if the effectiveness of each drug, patients will come to the clinic regularly to meet with the study team, complete questionnaires, and have blood work completed.

Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03464136?term=seavue&rank=1
Study Reference #: 71830

Lead Researcher (Principal Investigator)

Lead Researcher: Lawrence Saubermann

Study Contact Information

Study Coordinator: Cindy Doane
Phone: (585) 276-6019
Email: Cynthia_Doane@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Crohn Disease

Return to Search